Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD

Claire Bradley, Panos Alexandris, David R. Baldwin, Richard Booton, Mike Darby, Claire J. Eckert, Rhian Gabe, Neil Hancock, Sam Janes, Martyn Kennedy, Jason Lindop, Richard D. Neal, Suzanne Rogerson, Bethany Shinkins, Irene Simmonds, Sara Upperton, Jorgen Vestbo, Philip A.J. Crosbie, Matthew E.J. Callister

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction COPD is underdiagnosed, and measurement of spirometry alongside low-dose computed tomography (LDCT) screening for lung cancer is one strategy to increase earlier diagnosis of this disease. Methods Ever-smokers at high risk of lung cancer were invited to the Yorkshire Lung Screening Trial for a lung health check (LHC) comprising LDCT screening, pre-bronchodilator spirometry and a smoking cessation service. In this cross-sectional study we present data on participant demographics, respiratory symptoms, lung function, emphysema on imaging and both self-reported and primary care diagnoses of COPD. Multivariable logistic regression analysis identified factors associated with possible underdiagnosis and misdiagnosis of COPD in this population, with airflow obstruction defined as forced expiratory volume in 1 s/forced vital capacity ratio <0.70. Results Out of 3920 LHC attendees undergoing spirometry, 17% had undiagnosed airflow obstruction with respiratory symptoms, representing potentially undiagnosed COPD. Compared to those with a primary care COPD code, this population had milder symptoms, better lung function and were more likely to be current smokers (p⩽0.001 for all comparisons). Out of 836 attendees with a primary care COPD code who underwent spirometry, 19% did not have airflow obstruction, potentially representing misdiagnosed COPD, although symptom burden was high. Discussion Spirometry offered alongside LDCT screening can potentially identify cases of undiagnosed and misdiagnosed COPD. Future research should assess the downstream impact of these findings to determine whether any meaningful changes to treatment and outcomes occur, and to assess the impact on co-delivering spirometry on other parameters of LDCT screening performance such as participation and adherence. Additionally, work is needed to better understand the aetiology of respiratory symptoms in those with misdiagnosed COPD, to ensure that this highly symptomatic group receive evidence-based interventions.

Original languageEnglish
Article number00203-2023
JournalERJ Open Research
Volume9
Issue number4
DOIs
Publication statusPublished - 1 Jul 2023

Fingerprint

Dive into the research topics of 'Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD'. Together they form a unique fingerprint.

Cite this